|
Ameripath Announces Advanced Testing For Myeloproliferative Disorders |
|
|
|
30 Mar 2006 |
PALM BEACH GARDENS, FL, USA | Mar 29, 2006 | AmeriPath, Inc., a leading national provider of physician-based anatomic pathology, has developed a new assay that detects and quantifies a mutation in the Janus kinase 2 (JAK2) gene common in bcr/ablnegative myeloproliferative disorders (MPDs). The JAK2 V167F Mutation Analysis, available through both AmeriPath and Specialty Laboratories, can aid in or confirm the diagnosis of polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis, thereby giving physicians a dynamic new diagnostic tool to more effectively manage treatment decisions for improved patient outcomes.
With its maximized specificity and sensitivity, this new assay offers physicians the following:
• Potentially earlier and more confident diagnosis of bcr/abl-negative MPD patients
• Rapid, real-time PCR analysis for earlier implementation of appropriate treatment
• A quantitative result that provides a reference point for future patient assessments
“ We’re very excited about how this test can improve the assessment of myeloproliferative disorders,” said Russell L. Maiese, M.D., National Director of Hematopathology, AmeriPath, Inc. “It’s an outstanding development for AmeriPath, but more importantly, it’s a valuable one for our physicians and their patients.”
About AmeriPath, Inc.
AmeriPath, a leading national provider of physician-based anatomic pathology, dermatopathology and molecular diagnostic services to physicians, hospitals, clinical laboratories and surgery centers, supports community-based medicine by helping physicians provide excellent and effective care for their patients. A team of subspecialized pathologists and Ph.D. scientists provide medical expertise, diagnostic quality, and personal consultation services. AmeriPath’s team of more than 400 highly trained, board-certified pathologists and Ph.D.-level scientists provide medical diagnostics services in outpatient laboratories owned, operated and managed by AmeriPath, as well as in hospitals and ambulatory surgical centers.
About Specialty Laboratories, Inc.
Specialty Laboratories supports local pathology and community-based medicine by partnering with pathologists and hospitals to improve patient care and reduce episodesof- care costs. Specialty offers hospitals an extensive menu of highly advanced clinical tests used by physicians to diagnose, monitor, and treat disease and a single-source solution for esoteric testing needs. Specialty’s Web address is www.specialtylabs.com.
Media Contact:
Kelly Shaw
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
(770)475-2103
Interview Opportunity:
Russell L. Maiese, M.D.
National Director of Hematopathology
AmeriPath, Inc.
SOURCE: AmeriPath, Inc |
